METHOD FOR TREATING DISEASES ASSOCIATED WITH MODIFICATIONS OF QUALITATIVE AND/ QUANTITATIVE COMPOSITION OF BLOOD EXTRACELLULAR DNA (VARIANTS)
    84.
    发明申请
    METHOD FOR TREATING DISEASES ASSOCIATED WITH MODIFICATIONS OF QUALITATIVE AND/ QUANTITATIVE COMPOSITION OF BLOOD EXTRACELLULAR DNA (VARIANTS) 审中-公开
    用于处理与血液细胞外DNA(变体)的定性和/定量组合物相关的疾病的方法

    公开(公告)号:WO2005004904A1

    公开(公告)日:2005-01-20

    申请号:PCT/RU2004/000262

    申请日:2004-07-01

    Abstract: The invention relates to medicine and veterinary science. The inventive method for treating diseases associated with modifications of the qualitative and/or quantitative composition of blood extracellular DNA, namely oncological diseases, infection diseases provoked by bacteria, fungi and protozoa, atherosclerosis, pancreatic diabetes, allergic diseases associated with delayed response hypersensitivity and diseases due to somatic cell gene mutations consists in injecting a blood extracellular DNA binding agent in a systemic blood circulation. In a second variant, an agent modifying the chemical composition and/or conformation and/or polymery of the blood extracellular DNA without destruction thereof is injected into a systemic blood circulation. In a third variant, an agent stimulating the synthesis and/or the activity of endogenic biopolymers which bind or destroy or modify the chemical composition and/or conformation and/or polymery of the blood extracellular DNA without destruction thereof is injected into a systemic blood circulation.

    Abstract translation: 本发明涉及医学和兽医学。 用于治疗与血液细胞外DNA的定性和/或定量组成的修饰有关的疾病的本发明方法,即肿瘤疾病,由细菌,真菌和原生动物引起的感染性疾病,动脉粥样硬化,胰腺糖尿病,延迟反应超敏反应和疾病相关的过敏性疾病 由于体细胞基因突变包括在全身血液循环中注射血液细胞外DNA结合剂。 在第二种变体中,将血液细胞外DNA的化学组成和/或构象和/或聚合体修饰而不破坏的试剂注射到全身血液循环中。 在第三个变体中,刺激结合或破坏或改变血细胞外DNA的化学组成和/或构象和/或聚合而不破坏其的内源性生物聚合物的合成和/或活性的试剂注射到全身血液循环 。

    PERMANENT EPIGENETIC GENE SILENCING
    85.
    发明申请
    PERMANENT EPIGENETIC GENE SILENCING 审中-公开
    永久性基因沉默

    公开(公告)号:WO2016063264A1

    公开(公告)日:2016-04-28

    申请号:PCT/IB2015/058202

    申请日:2015-10-23

    Abstract: A product comprising two or more artificial transcription repressors (ATRs), or polynucleotides encoding therefor, selected from groups (a), (b), (c) or (d): (a) an ATR comprising a DNA-binding domain operably linked to a KRAB domain or homologue thereof; (b) an ATR comprising a DNA-binding domain operably linked to a DNMT3A, DNMT3B or DNMT1 domain or homologue thereof; (c) an ATR comprising a DNA-binding domain operably linked to a DNMT3L domain or homologue thereof; and (d) an ATR comprising a DNA-binding domain operably linked to a SETDB1 domain or homologue thereof, wherein at least two of the ATRs are selected from different groups (a), (b), (c) or (d).

    Abstract translation: 选自(a),(b),(c)或(d)组的两种或更多种人工转录阻抑物(ATR)或其编码的多核苷酸的产物:(a)包含可操作地连接的DNA结合结构域的ATR 到KRAB结构域或其同源物; (b)ATR,其包含与DNMT3A,DNMT3B或DNMT1结构域或其同源物可操作地连接的DNA结合结构域; (c)包含可操作地连接到DNMT3L结构域或其同源物的DNA结合结构域的ATR; 和(d)ATR,其包含可操作地连接到SETDB1结构域或其同源物的DNA结合结构域,其中至少两个ATR选自不同的组(a),(b),(c)或(d)。

Patent Agency Ranking